ÖZ
Olanzapin, ikinci kuşak bir antipsikotiktir ve dopamin antagonizması nedeniyle prolaktin seviyelerinin yükselmesine neden olabilir. İkinci kuşak antipsikotiklerde belirgin hiperprolaktinemi riskinin görece düşük olduğu düşünülse de, bazı çalışmalar olanzapin ile olan prolaktin artışlarını bildirmektedir. Ancak olanzapin kullanımına bağlı klinik semptomlar olan amenore ve galaktore nadiren bildirilmiştir. Bu olguda, bipolar bozukluk tanısıyla uzun süredir olanzapin tedavisi alan bir kız ergenin, psikotik belirtileri nedeniyle olanzapin dozu 20 mg/gün’e yükseltildikten on hafta sonra, ikincil amenore gelişmiş ve prolaktin düzeyi 38,7 µg/L saptanmıştır. Olanzapin dozunun 10 mg/gün’e düşürüldükten dört hafta içinde prolaktin seviyeleri normale dönmüş ve menstrüasyon yeniden başlamıştır. Bu olgunun dikkat çekici yönü, olanzapinle ilişkili hiperprolaktinemi olgularının adolesanlarda nadiren bildirilmesinin yanında, olanzapinle ilişkili ikincil amenorenin bildiğimiz kadarıyla literatürde ergenlerde daha önce bildirilmemiş olmasıdır.
Anahtar Kelimeler:
Hiperprolaktinemi, ikincil amenore, olanzapine
Kaynaklar
1Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2007;3:579-587.
2David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22:1085-1096.
3Krøigaard SM, Clemmensen L, Tarp S, Pagsberg AK. A meta-analysis of antipsychotic-induced hypo- and hyperprolactinemia in children and adolescents. J Child Adolesc Psychopharmacol. 2022;32:374-389.
4Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65:57-61.
5Migliardi G, Spina E, D’Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, de Leon J. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1496-1501.
6Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12:83-91.
7APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
8Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone induced hyperprolactinemia: from basic to clinical studies. Front Psychiatry. 2022;13:874705.
9Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 2016;6:185-190.
10Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J Clin Psychiatry. 2003;64:1192-1194.
11Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009;29:278-283.
12Wu XL, Wang JH, Hu SH, Tao J. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Arch Psychiatry. 2012;22:7-11.
13Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107:218-222.
14American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. 2011.
15National Collaborating Centre for Mental Health (Great Britain). Psychosis and schizophrenia in children and young people: recognition and management. London: National Institute for Health and Care Excellence; 2013.
